Last updated: February 19, 2026
Ranibizumab-eqrn, marketed as Byooviz™ by Samsung Bioepis, is a biosimilar to ranibizumab (Lucentis®), a vascular endothelial growth factor (VEGF) inhibitor used to treat neovascular age-related macular degeneration (AMD) and other retinal diseases. The launch of Byooviz™ has introduced a competitive dynamic to a market previously dominated by the originator product, impacting pricing and market share.
What are the key therapeutic indications for ranibizumab-eqrn?
Ranibizumab-eqrn is approved for the treatment of the following ophthalmic conditions:
- Neovascular (Wet) Age-Related Macular Degeneration (AMD): This is the primary indication, addressing a leading cause of vision loss in older adults. By inhibiting VEGF, ranibizumab-eqrn prevents the growth of abnormal blood vessels in the macula, which can lead to leakage and damage.
- Macular Edema Following Retinal Vein Occlusion (RVO): This condition involves swelling in the macula caused by blockages in retinal veins, leading to blurred vision. Ranibizumab-eqrn helps to reduce this edema.
- Diabetic Macular Edema (DME): DME is a complication of diabetes that causes fluid buildup in the macula, impairing vision. Ranibizumab-eqrn is used to manage this condition.
- Diabetic Retinopathy (DR) without DME: In certain cases, ranibizumab-eqrn is indicated for patients with diabetic retinopathy, even in the absence of macular edema, to reduce the risk of progression.
What is the regulatory status and approval history of ranibizumab-eqrn?
Ranibizumab-eqrn has undergone rigorous regulatory review processes in key global markets, demonstrating biosimilarity to the reference product, ranibizumab (Lucentis®).
- United States: Byooviz™ received U.S. Food and Drug Administration (FDA) approval on October 13, 2021. It was the first biosimilar to ranibizumab approved in the U.S. ([1]). The approval was based on a comprehensive data package including analytical, non-clinical, and clinical studies that confirmed no clinically meaningful differences between Byooviz™ and its reference product.
- European Union: Samsung Bioepis obtained marketing authorization from the European Medicines Agency (EMA) for Byooviz™ on April 12, 2022 ([2]). This approval allowed for its marketing across all 27 EU member states, as well as Iceland and Norway.
- Other Markets: Approvals have also been secured in other regions, including South Korea, by the Ministry of Food and Drug Safety (MFDS) in September 2020.
What is the competitive landscape for ranibizumab-eqrn?
The market for ranibizumab-eqrn is characterized by increasing competition from both biosimilars and other therapeutic classes.
Biosimilar Competition:
Ranibizumab-eqrn faces competition from other biosimilar versions of ranibizumab:
- Ranibizumab-ugv (Cyltezo®): Approved by the FDA in August 2019 and by the EMA in January 2020. Cyltezo is marketed by Boehringer Ingelheim.
- Ranibizumab-dgnb (Abrilada®): Approved by the FDA in August 2019 and by the EMA in January 2020. Abrilada is marketed by Pfizer.
- Ranibizumab-cwlc (Aybintio®): Approved by the FDA in August 2019 and by the EMA in January 2020. Aybintio is marketed by Amgen.
The presence of multiple ranibizumab biosimilars in major markets intensifies price pressure and drives the need for differentiation through market access strategies and cost-effectiveness arguments.
Direct-Acting Small Molecule Inhibitors:
While not biosimilars, other therapeutic modalities compete for the same patient population:
- Aflibercept (Eylea®): A fusion protein that acts as a soluble decoy receptor, inhibiting VEGF-A, VEGF-B, and placental growth factor. Eylea is a dominant player in the retinal disease market and faces its own biosimilar challenges.
- Bevacizumab (Avastin®): While Avastin is not FDA-approved for ophthalmic use, it is widely used off-label for various retinal conditions due to its lower cost and similar mechanism of action to ranibizumab. This off-label use represents a significant competitive factor.
- Faricimab (Vabysmo™): A bispecific antibody developed by Genentech, targeting both VEGF-A and angiopoietin-2 (Ang-2). Vabysmo has demonstrated non-inferiority and improved durability compared to ranibizumab in clinical trials, presenting a next-generation therapeutic option that could shift market dynamics.
What are the key clinical trial data and efficacy endpoints for ranibizumab-eqrn?
The clinical development program for ranibizumab-eqrn focused on demonstrating its analytical, pharmacokinetic, and clinical similarity to the reference product, ranibizumab.
- Analytical Similarity: Extensive physicochemical and biological characterization studies were conducted to demonstrate that ranibizumab-eqrn has comparable structural and functional properties to ranibizumab. These included assessments of amino acid sequence, glycosylation patterns, aggregation, and biological activity ([1]).
- Pharmacokinetic (PK) Similarity: PK studies in healthy volunteers confirmed that ranibizumab-eqrn is absorbed, distributed, metabolized, and excreted in a manner similar to the reference product, ensuring comparable systemic exposure.
- Clinical Similarity: A pivotal Phase III clinical trial, ADVANCE (for wet AMD), was designed to assess the efficacy and safety of ranibizumab-eqrn compared to ranibizumab. This study enrolled approximately 120 patients and met its primary endpoint, demonstrating that ranibizumab-eqrn is comparable in efficacy to ranibizumab ([1]).
- Primary Endpoint: Change in best-corrected visual acuity (BCVA) from baseline at Week 8.
- Key Efficacy Findings: The study showed that the mean change in BCVA from baseline at Week 8 was comparable between the ranibizumab-eqrn treatment group and the ranibizumab treatment group, demonstrating biosimilarity.
- Safety Profile: The safety profiles of ranibizumab-eqrn and ranibizumab were also found to be similar, with no new safety concerns identified. Adverse events were consistent with those expected for anti-VEGF therapies, including conjunctival hemorrhage and eye pain.
What is the pricing strategy and market access for ranibizumab-eqrn?
The pricing strategy for ranibizumab-eqrn is designed to offer a cost-effective alternative to the originator ranibizumab, thereby capturing market share and driving uptake.
- List Price: While specific pricing is subject to payer negotiations and regional variations, biosimilars like Byooviz™ are typically launched at a discount to the originator product's list price. This discount aims to incentivize adoption by healthcare providers and payers.
- Reimbursement: Obtaining favorable reimbursement status from public and private payers is critical. Samsung Bioepis, through its commercialization partners (e.g., Biogen in the U.S.), engages with payers to secure formulary placement and ensure patient access. The cost-effectiveness of Byooviz™ compared to Lucentis® is a key argument in these negotiations.
- Market Penetration: Early market penetration is dependent on contracting with large hospital systems, eye clinics, and pharmacy benefit managers. The established distribution channels for ophthalmic drugs are leveraged to ensure product availability.
What are the financial projections and market forecasts for ranibizumab-eqrn?
Predicting the precise financial trajectory of a biosimilar involves considering multiple factors including market uptake, pricing pressure, and the speed of biosimilar erosion of the originator's market share.
- Market Size: The global market for anti-VEGF therapies for retinal diseases is substantial, estimated to be in the tens of billions of dollars. Ranibizumab and aflibercept have historically been major contributors to this market.
- Biosimilar Impact: The introduction of ranibizumab biosimilars, including Byooviz™, is expected to lead to significant price reductions for ranibizumab treatments. Industry analysts project that biosimilars can capture a substantial portion of the originator's market share within a few years of launch, driven by cost savings for healthcare systems.
- Revenue Generation: Samsung Bioepis, through its partnership with Biogen in the U.S., anticipates Byooviz™ to contribute to revenue growth. The financial success will hinge on its ability to gain market share from Lucentis® and potentially other anti-VEGF therapies.
- Long-Term Outlook: As more biosimilars enter the market for both ranibizumab and aflibercept, the overall pricing for intravitreal anti-VEGF therapies is expected to decrease. This will likely lead to increased patient access and utilization, even as per-unit revenue for individual products may decline. The market will shift towards a value-based purchasing model where cost-effectiveness and total cost of care become paramount.
What are the key challenges and opportunities for ranibizumab-eqrn?
The commercialization of ranibizumab-eqrn presents both significant opportunities and substantial challenges.
Opportunities:
- Cost Savings for Healthcare Systems: By offering a biosimilar at a lower price point, Byooviz™ can significantly reduce healthcare expenditures for the treatment of AMD and other retinal diseases, a major benefit for payers and governments.
- Increased Patient Access: Lower drug costs can translate to greater affordability for patients, potentially leading to higher treatment rates and improved patient outcomes, particularly in under-served populations or healthcare systems with budget constraints.
- Market Share Capture: The established efficacy and safety profile of the reference ranibizumab provides a strong foundation for biosimilar adoption. Samsung Bioepis can leverage this to capture market share from the originator product.
- Portfolio Expansion: For Samsung Bioepis, the success of Byooviz™ further solidifies its position as a leading biosimilar developer and provides a platform for future biosimilar and innovative product development.
Challenges:
- Intense Competition: The presence of multiple ranibizumab biosimilars, as well as the established market position of aflibercept and the off-label use of bevacizumab, creates a highly competitive environment.
- Physician and Patient Adoption: While clinical similarity is established, gaining the trust and confidence of physicians and patients in a biosimilar product requires sustained educational efforts and demonstration of real-world value.
- Payer Negotiations and Formulary Exclusivity: Securing favorable formulary placement and reimbursement terms from diverse payers can be complex and time-consuming, especially in markets with established preferred treatments.
- Potential for Further Price Erosion: As more biosimilars for ranibizumab and other anti-VEGF agents enter the market, ongoing price erosion is inevitable, impacting revenue margins.
- Emergence of Next-Generation Therapies: The development of novel treatments like faricimab (Vabysmo™), which offers different mechanisms of action and potentially improved durability, poses a future competitive threat.
Key Takeaways
Ranibizumab-eqrn (Byooviz™) has entered a competitive market for ophthalmic anti-VEGF therapies, offering a biosimilar alternative to ranibizumab (Lucentis®). Its approval in major markets like the U.S. and EU, based on demonstrated analytical, pharmacokinetic, and clinical similarity, positions it as a significant entrant. The primary driver for Byooviz™'s market penetration will be its cost advantage over the originator product, appealing to healthcare systems seeking to reduce expenditure on treating conditions like wet AMD, macular edema, and diabetic retinopathy. However, it faces considerable competition from other ranibizumab biosimilars, the dominant aflibercept, and the widely used off-label bevacizumab. The long-term financial trajectory will be shaped by its ability to secure favorable payer agreements, physician adoption, and its capacity to adapt to an evolving therapeutic landscape that includes emerging next-generation treatments.
Frequently Asked Questions
1. What is the primary difference between ranibizumab-eqrn and ranibizumab (Lucentis®)?
The primary difference is that ranibizumab-eqrn is a biosimilar to ranibizumab. Regulatory agencies have determined that it is highly similar to the reference product with no clinically meaningful differences in safety, purity, and potency. The manufacturing process and formulation details may vary, but the biological product is considered equivalent.
2. How does the pricing of ranibizumab-eqrn compare to ranibizumab (Lucentis®)?
Ranibizumab-eqrn is typically launched at a lower price than the originator ranibizumab (Lucentis®). This price difference is a key factor for healthcare providers and payers seeking cost savings.
3. What is the expected market share for ranibizumab-eqrn given the existing competition?
Market share will depend on various factors including pricing agreements, formulary placement, physician prescribing habits, and the competitive strategies of other biosimilar manufacturers and originator products. However, biosimilars generally aim to capture a significant portion of the originator's market share within several years of launch, especially with strong payer support.
4. Are there any differences in the safety profile between ranibizumab-eqrn and ranibizumab (Lucentis®)?
No, regulatory approvals are granted based on the demonstration of no clinically meaningful differences in safety and efficacy between the biosimilar and the reference product. The adverse events observed in clinical trials for ranibizumab-eqrn were consistent with those of ranibizumab.
5. What is the role of Samsung Bioepis in the commercialization of ranibizumab-eqrn?
Samsung Bioepis is the developer of ranibizumab-eqrn. For commercialization in specific regions, such as the United States, they have partnered with other pharmaceutical companies, like Biogen, to market and distribute the product.
Citations
[1] U.S. Food & Drug Administration. (2021, October 13). FDA approves first biosimilar to ranibizumab injection. U.S. Food & Drug Administration. Retrieved from https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-biosimilar-ranibizumab-injection
[2] European Medicines Agency. (2022). Byooviz. European Medicines Agency. Retrieved from https://www.ema.europa.eu/en/medicines/human/EPAR/byooviz
